Keyphrases
Schistosomiasis
66%
Antischistosomal
66%
Chemotype
66%
Hydantoin
50%
Antischistosomal Drugs
50%
Aryl
50%
In Vivo Activity
33%
Ozonide
33%
Carboxylic Acids
33%
Novel Mechanism of Action
33%
Antischistosomal Activity
33%
Physicochemical Profiling
33%
Drug Development
33%
Urea
33%
New Drugs
33%
Androgen Receptor
33%
Parasite Stages
33%
Iterative Feedback
25%
Progression Criteria
25%
Antiandrogen
16%
Receptor Binding Affinity
16%
Parasitic Diseases
16%
In Silico
16%
Binding Studies
16%
Praziquantel
16%
Integrated Control Programs
16%
Fluke
16%
In Vitro ADME
16%
Tropical Parasitic Diseases
16%
Diversity-guided
16%
Schistosoma
16%
Resistance Development
16%
Design Strategy
16%
Orally Active
16%
Mechanism of Action Studies
16%
Compound Design
16%
Drug Target
16%
N,N′-Diarylureas
16%
Structural Diversity
16%
Infection Risk
16%
Scale Usage
16%
Expected Outcomes
16%
Mechanistic Investigation
16%
Receptor-ligand Binding
16%
Specific Intent
16%
Structural Assumption
16%
Pharmacokinetic Effects
16%
New Therapeutic Approaches
16%
In Vitro Cytotoxicity
16%
SAR Data
16%
Multidrug-resistant
16%
Curb
16%
Last Resort
16%
Chemotherapy
16%
Medicine and Dentistry
Schistosomiasis
100%
Hydantoin Derivative
75%
In Vitro
75%
Carboxylic Acid
50%
Androgen Receptor
50%
Absorption Distribution Metabolism Excretion
50%
Parasite (Microbiology)
50%
Parasitic Disease
50%
Infection
50%
Receptor Binding
25%
In Silico
25%
Side Effect
25%
Pharmacokinetics
25%
Cytotoxicity
25%
Binding Affinity
25%
Single Drug Dose
25%
Ex Vivo
25%
Fluke
25%
Action Study
25%
Schistosoma
25%
Ligand Binding
25%
Praziquantel
25%
Pharmacology, Toxicology and Pharmaceutical Science
Schistosomiasis
100%
Hydantoin Derivative
75%
Drug Development
50%
Carboxylate
50%
Ozonide
50%
Parasitosis
50%
Infection
50%
Structure Activity Relationship
50%
Absorption Distribution Metabolism Excretion
50%
Androgen Receptor
50%
Schistosoma
25%
Trematode
25%
Chemotherapy
25%
Pharmacokinetics
25%
Cytotoxicity
25%
Side Effect
25%
Praziquantel
25%